Published in Medical Letter on the CDC and FDA, August 8th, 2004
The company anticipates receiving final approval and launching its generic product following the resolution of the patent challenge litigation surrounding this product.
Allegra-D is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Allegra-D had annual sales of approximately $450...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA